Revolution Medicines (Revolution Medicines) Retained Earnings : $-1,137.71 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Revolution Medicines's retained earnings for the quarter that ended in Dec. 2023 was $-1,137.71 Mil.

Revolution Medicines's quarterly retained earnings declined from Jun. 2023 ($-867.74 Mil) to Sep. 2023 ($-976.17 Mil) and declined from Sep. 2023 ($-976.17 Mil) to Dec. 2023 ($-1,137.71 Mil).

Revolution Medicines's annual retained earnings declined from Dec. 2021 ($-452.64 Mil) to Dec. 2022 ($-701.34 Mil) and declined from Dec. 2022 ($-701.34 Mil) to Dec. 2023 ($-1,137.71 Mil).

Revolution Medicines Retained Earnings Historical Data

The historical data trend for Revolution Medicines's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines Retained Earnings Chart

Revolution Medicines Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-157.39

-265.55

-452.64

-701.34

-1,137.71

Revolution Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-701.34	-769.44	-867.74	-976.17	-1,137.71

Revolution Medicines Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Revolution Medicines (NAS:RVMD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Revolution Medicines (Revolution Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

42Z:Germany

Address

700 Saginaw Drive, Redwood City, CA, USA, 94063

Website

https://www.revmed.com

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Executives

Stephen Michael Kelsey	officer: See Remarks	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Jeff Cislini	officer: General Counsel	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark A Goldsmith	director, officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Margaret A Horn	officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Anders	officer: Chief Financial Officer	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barbara Weber	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Xiaolin Wang	officer: See Remarks	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Thilo Schroeder	director	C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Lorence H. Kim	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Sushil Patel	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Peter Svennilson	director, 10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Vincent A. Miller	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139